Novel molecular targets for the therapy of urothelial carcinoma

Bagi Jana, Matthew D. Galsky, Noah M. Hahn, Matthew I. Milowsky, Guru Sonpavde

    Research output: Contribution to journalArticle

    2 Scopus citations

    Abstract

    Introduction: First-line platinum-based combinations are active in locally advanced and metastatic urothelial carcinoma; however, long-term outcomes including disease-specific and overall survival remain suboptimal. In addition, approximately 40 50% of patients with advanced urothelial carcinoma have coexisting medical issues that preclude the use of cisplatin-based therapy. Improvements in our understanding of the molecular mechanisms of urothelial tumorigenesis have led to first-generation clinical trials evaluating novel agents targeting molecular pathways. These are particularly relevant in regard to subpopulations. Novel trial designs warrant consideration to accelerate accrual. Areas covered: In this review, novel molecular targets for the therapy of urothelial carcinoma, as well as recently completed and ongoing clinical trials utilizing novel targeted agents, are discussed. A Medline search with key words, abstracts reported at national conferences on urothelial carcinoma and NCI clinical trial identifiers was used for this review. Expert opinion: Improved understanding of molecular biology has identified a number of new molecular targets, but there is a seeming absence of one dominant molecular driver for urothelial cancer. An adaptive and biomarker-derived strategy may be warranted. Clinical trials utilizing targeted agents are ongoing and results are awaited.

    Original languageEnglish (US)
    Pages (from-to)499-513
    Number of pages15
    JournalExpert Opinion on Therapeutic Targets
    Volume16
    Issue number5
    DOIs
    StatePublished - May 2012

      Fingerprint

    Keywords

    • Novel molecular targets
    • Targeted therapy
    • Transitional cell carcinoma
    • Urothelial carcinoma

    ASJC Scopus subject areas

    • Drug Discovery
    • Pharmacology
    • Clinical Biochemistry
    • Molecular Medicine

    Cite this

    Jana, B., Galsky, M. D., Hahn, N. M., Milowsky, M. I., & Sonpavde, G. (2012). Novel molecular targets for the therapy of urothelial carcinoma. Expert Opinion on Therapeutic Targets, 16(5), 499-513. https://doi.org/10.1517/14728222.2012.677441